GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » EBITDA Margin %

Nxera Pharma Co (Nxera Pharma Co) EBITDA Margin % : -2.78% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nxera Pharma Co's EBITDA for the three months ended in Dec. 2023 was $-1.41 Mil. Nxera Pharma Co's Revenue for the three months ended in Dec. 2023 was $50.65 Mil. Therefore, Nxera Pharma Co's EBITDA margin for the quarter that ended in Dec. 2023 was -2.78%.


Nxera Pharma Co EBITDA Margin % Historical Data

The historical data trend for Nxera Pharma Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co EBITDA Margin % Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.87 40.15 31.10 20.42 -44.70

Nxera Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.73 -143.59 -111.14 -80.05 -2.78

Competitive Comparison of Nxera Pharma Co's EBITDA Margin %

For the Biotechnology subindustry, Nxera Pharma Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's EBITDA Margin % falls into.



Nxera Pharma Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nxera Pharma Co's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-39.637/88.664
=-44.70 %

Nxera Pharma Co's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.41/50.645
=-2.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nxera Pharma Co  (OTCPK:SOLTF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Nxera Pharma Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (Nxera Pharma Co) Business Description

Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (Nxera Pharma Co) Headlines

From GuruFocus